Armata Pharmaceuticals (ARMP) Cash from Operations (2013 - 2026)
Armata Pharmaceuticals (ARMP) posted Cash from Operations of 5782000.0 for Q1 2026, up 13.37% sequentially from 6674000.0 in Q4 2025, and up 23.72% YoY from 4673444.23 in Q1 2025.
Armata Pharmaceuticals (ARMP) Cash from Operations (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Cash from Operations for 14 years, with the latest figure at 5782000.0 in Q1 2026.
- Quarterly Cash from Operations rose 23.72% year-over-year to 5782000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23965000.0 (up 30.63% YoY) and the FY2025 annual result came in at 25763000.0, up 31.39% from the prior year.
- Cash from Operations advanced to 5782000.0 in Q1 2026 per ARMP's latest filing, from 6674000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 3515000.0 in Q1 2022 and troughed at 17570000.0 in Q1 2023.
- A 5-year average of 8764705.88 and a median of 8148000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations slumped 399.86% in 2023, then soared 51.51% in 2025.
- Over 5 years, Cash from Operations stood at 10485000.0 in 2022, then gained by 22.69% to 8106000.0 in 2023, then grew by 2.21% to 7927000.0 in 2024, then grew by 15.81% to 6674000.0 in 2025, then gained by 13.37% to 5782000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 5782000.0, 6674000.0, and 4298000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Armata Pharmaceuticals | 182.82 Mn | 158.82 Mn | - | -8.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.67 Mn |
| Jun 30, 2026 | -8.67 Mn |
| Mar 31, 2026 | -5.78 Mn |
| Mar 31, 2026 | -5.78 Mn |
| Dec 31, 2025 | -6.67 Mn |
| Dec 31, 2025 | -6.67 Mn |
| Sep 30, 2025 | -4.30 Mn |
| Sep 30, 2025 | -4.30 Mn |
| Jun 30, 2025 | -7.21 Mn |
| Jun 30, 2025 | -7.21 Mn |
| Mar 31, 2025 | -7.58 Mn |
| Mar 31, 2025 | -7.58 Mn |
| Dec 31, 2024 | -7.93 Mn |
| Dec 31, 2024 | -7.93 Mn |
| Sep 30, 2024 | -8.86 Mn |
| Sep 30, 2024 | -8.86 Mn |
| Jun 30, 2024 | -10.18 Mn |
| Jun 30, 2024 | -10.18 Mn |
| Mar 31, 2024 | -10.58 Mn |
| Mar 31, 2024 | -10.58 Mn |